Palvella Therapeutics (PVLA) Capital Expenditures Growth (1y) (2015 - 2023)
Palvella Therapeutics (PVLA) Capital Expenditures Growth (1y) (2015 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,912.31 Bn | 1,912.25 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.15 Bn | 462.36 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 123.00 Bn | 115.76 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.22 Bn | 61.47 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.57 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.70 Bn | 34.69 Bn | 959.66 Mn | 143.40% |
| 10 | Palvella Therapeutics | 1.85 Bn | 1.59 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -101.29% |
| Sep 30, 2023 | 106.99% |
| Jun 30, 2023 | -89.35% |
| Mar 31, 2023 | -87.66% |
| Dec 31, 2022 | 195.32% |
| Sep 30, 2022 | -382.00% |
| Jun 30, 2022 | 174.67% |
| Mar 31, 2022 | 1,289.29% |
| Dec 31, 2021 | -40.83% |
| Sep 30, 2021 | 141.67% |
| Jun 30, 2021 | -78.42% |
| Mar 31, 2021 | -98.55% |
| Dec 31, 2020 | -50.85% |
| Sep 30, 2020 | -462.07% |
| Jun 30, 2020 | 13.72% |
| Mar 31, 2020 | 1,492.56% |
| Dec 31, 2019 | 108.14% |
| Sep 30, 2019 | -28.62% |
| Jun 30, 2019 | 136.80% |
| Mar 31, 2019 | -70.77% |